2- (4- (4- chloro- 1,2- diphenyl- but- 1- enyl)phenoxy)ethanol

Subscribe to Selected New Research on 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol

18 relevant articles (1 outcomes, 2 trials/studies) found for this Bio-Agent

Description: structure in first source

Also Known As:

FC-1271a; Ospemifene; Z-2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Benzene Derivatives: 9

Benzylidene Compounds

Stilbenes: 39

Tamoxifen: 7586

2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol: 18

Experts

1.	Yu, Qilu: 1 article (11/2005)
2.	Degregorio, Michael W: 1 article (11/2005)
3.	Read, Karla C: 1 article (11/2005)
4.	Gregg, Jeffrey P: 1 article (11/2005)
5.	Beckett, Laurel A: 1 article (11/2005)
6.	Wurz, Gregory T: 1 article (11/2005)
7.	Marchisano-Karpman, Cristina: 1 article (11/2005)
8.	DeGregorio, M W: 1 article (06/2001)
9.	Taras, T L: 1 article (06/2001)
10.	Wurz, G T: 1 article (06/2001)

Related Diseases

1.	Osteoporosis 09/01/2003 - "Such effects would be advantageous if ospemifene were found to be effective in the long-term prevention of osteoporosis." 09/01/2003 - "OBJECTIVE: Ospemifene, a novel selective estrogen receptor modulator, shows a potential for prevention and treatment of osteoporosis in postmenopausal women" 06/01/2001 - "Ospemifene (FC-1271a) is a novel selective estrogen receptor modulator under development for osteoporosis prevention" 11/01/2005 - "The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects." 11/01/2005 - "Ospemifene is a new selective estrogen receptor modulator (SERM) that is being developed for the treatment of urogenital atrophy and osteoporosis" Get all the results and reference details, order at left...
2.	Atrophy 03/01/2005 - "Further studies with ospemifene are needed in subjects with vaginal atrophy." 06/01/2008 - "Ospemifene (Ophena) is a new selective oestrogen receptor modulator currently in phase III clinical development for treatment of post-menopausal vulvar and vaginal atrophy" 01/01/2006 - "Ospemifene is a novel selective estrogen receptor modulator (SERM) that is initially being developed for the treatment of vaginal atrophy in postmenopausal women" 11/01/2005 - "The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects." 11/01/2005 - "Ospemifene is a new selective estrogen receptor modulator (SERM) that is being developed for the treatment of urogenital atrophy and osteoporosis" Get all the results and reference details, order at left...
3.	Breast Neoplasms (Breast Cancer) 06/01/2001 - "In vitro, the growth inhibitory effects of FC-1271a and its main metabolite are investigated in MCF-7 and MDA-MB-231 human breast cancer cells at doses ranging from 0.1 to 10 microM" 06/01/2001 - "In the present paper, we examine both the in vitro and in vivo effects of FC-1271a in breast cancer models" 06/01/2001 - "In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer." 11/01/2005 - "Similarly to other SERMs, ospemifene exhibits antiestrogenic effects in breast tissue, which led to the hypothesis that it may be a potential breast cancer chemopreventive agent" 11/01/2005 - "The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects." Get all the results and reference details, order at left...
4.	Carcinoma (Carcinomatosis) 11/01/2005 - "The results of the follow-up study, which extended the treatment to 52 weeks, confirmed the results of our previous study, with ospemifene (p = 0.01) and tamoxifen (p = 0.004) significantly decreasing mammary carcinomas compared to controls" 01/01/2005 - "CONCLUSION: Tamoxifen and ospemifene inhibit the growth of premalignant mammary lesions and the progression to invasive carcinoma in a transplantable mouse model of DCIS" 11/01/2005 - "As hypothesized, ospemifene greatly reduced the incidence of mammary carcinomas compared to control mice (p = 0.003), similar to tamoxifen (p = 0.0004); however, in the raloxifene group, no significant effect was seen in mammary tumor prevention (p = 0.20)" Get all the results and reference details, order at left...
5.	Neoplasms (Cancer) 11/01/2005 - "Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice." 06/01/2001 - "FC-1271a and TOR VI did not inhibit the growth of MDA-MB-231 cells in vitro, and no clear effects of FC-1271a treatment were seen on MDA-MB-231 tumor growth in vivo" 06/01/2001 - "Treatment with FC-1271a in vivo inhibited MCF-7 tumor growth, compared with control (P< or =0.05)" 06/01/2001 - "In vivo, the effects of treatment with 10, 25, 50, or 100 mg/kg FC-1271a on MCF-7 and MDA-MB-231 human tumor xenografts in athymic, ovariectomized mice were determined" 01/01/2006 - "As expected, ospemifene (p = 0.01) and tamoxifen (p = 0.004) significantly reduced the incidence of mammary tumors compared to the control mice, which had a mammary tumor incidence of approximately 57%" Get all the results and reference details, order at left...
15 Diseases and 18 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Selective Estrogen Receptor Modulators (SERM)
3.	LY 353381 (LY353381)
4.	Raloxifene (Evista)
5.	Succinic Acid (Succinate)
6.	Sodium
7.	Daptomycin
8.	Toremifene (Fareston)
9.	Yttrium
10.	Mesylates (Mesylate)
228 Drugs and Important Bio-Agents and 15 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Stents
2.	Heterologous Transplantation (Xenotransplantation)
2 Therapies and Procedures and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>